Scholarships / Fellowships
|
2022-2023 |
|||
|
Motor imbalance in Parkinson patients: Its relation to multi-sensory integration |
|||
|
|
Quantitative Analysis of Blood-Brain Barrier Dysfunction in Parkinson's Disease using Dynamic Contrast-Enhanced MRI |
|||
|
|
Amyloid-like fibrils of lipids – novel cause of Parkinson's in sphingolipidoses
|
|||
|
|
Regulating molecular aging by the engineering of a bispecific CTLA4-VISTA for a tunable immune response |
|||
|
|
The involvement of ApoE4 in Parkinson's Disease |
|||
|
|
Targeting CD157+ myeloid cells during Parkinson’s Disease |
|||
|
|
Metabolite self-assembly in Parkinson’s |
|||
|
|
Brain imaging changes in neurodegenerative diseases: An advanced MRI study |
|||
|
|
Intracellular seeding of α-synuclein aggregation by self-assemblies |
|||
|
|
2021-2022 |
|||
|
Establishing an in vitro platform for studying a-Syn aggregates propagation |
|||
|
|
The transcriptomic basis of THC micro-dose induced neuroprotection |
|||
|
|
A novel machine learning system for manual dexterity training in patients with PD |
|||
|
|
The involvement of APOE4 in Parkinson's disease |
|||
|
|
The role of extracellular vesicles in the progression and pathology of PD |
|||
|
|||
|
2020- 2021 |
|
Seeding of amyloids in Parkinson's disease: The involvement of neurometabolites assemblies in the initiation of pathological processes |
|||
|
|
Glucosylceramide, a major substrate in Gaucher disease forms amyloid-like fibrils that induce α-Synuclein aggregation. |
|||
|
|
Establishing an in vitro platform for studying α-Syn aggregates propagation |
|||
|
|
Characterization of α-Synuclein secretion mechanisms in Parkinson's disease |
|||
|
|
Amyloid-like aggregates of a Gaucher disease metabolite seed aggregation of α-Synuclein: Mechanism and development of novel therapeutics for Parkinson’s disease |
|||
|
|
Establishing alpha-synuclein aggregates traits in peripheral human tissues and biofluids as new Parkinson’s disease biomarkers |
|||
|
|
Elucidating the role and underlying mechanisms of Rab12 functions |
|||
|
|
Treatment of LRRK2-related Parkinson’s patients through immunotherapy |
|||
|
|
2019-2020 |
|||
|
Testing a Possible Genetic Interaction Between GBA1 and LRRK2 |
|||
|
|
Rotenone Toxicity Cellular Model to Test SKIP as a Disease-Modifying Intervention |
|||
|
|
Mechanisms of Post-Transcriptional Modifications in the Regulation of Mammalian Macroautophagy |
|||
|
|
The Molecular Mechanism of GDNF Transport in Parkinson Disease |
|||
|
|
Developing a Super-Resolution Microscopy Platform for Early Detection of Alpha Synuclein Aggregation in Human Body Fluids |
|||
|
|
Amyloid-like fibrils of lipids – novel cause of Parkinson's in sphingolipidoses |
|||
|
|
Regulating molecular aging by the engineering of a bispecific CTLA4-VISTA for a tunable immune response |
|||
|
|
The involvement of ApoE4 in Parkinson's Disease |
|||
|
|
Targeting CD157+ myeloid cells during Parkinson’s Disease |
|||
|
|
Metabolite self-assembly in Parkinson’s |
|||
|
|
Brain imaging changes in neurodegenerative diseases: An advanced MRI study |
|||
|
|
Intracellular seeding of α-synuclein aggregation by self-assemblies |
|||
|
